Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK Neisseria gonorrhoeae GMMA vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The GSK Neisseria gonorrhoeae GMMA (NgG) vaccine is an investigational biologic vaccine developed by GSK to prevent gonorrhea, a sexually transmitted infection caused by the bacterium *Neisseria gonorrhoeae*. The vaccine utilizes Generalized Modules for Membrane Antigens (GMMA) technology, which consists of genetically detoxified outer membrane vesicles (OMVs) derived from the *N. gonorrhoeae* FA1090 strain. These vesicles are engineered to reduce endotoxin activity and carry a broad range of bacterial antigens, including lipooligosaccharide and various outer membrane proteins, to elicit a functional immune response against multiple gonococcal strains. It is currently being evaluated in Phase 1/2 clinical trials and has received Fast Track designation from the FDA.
- Other names
- GSK Neisseria gonorrhoeae GMMA (NgG) vaccineNgG investigational vaccine
02
Targets
N. gonorrhoeae (Neisseria gonorrhoeae)TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on GSK Neisseria gonorrhoeae GMMA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK Neisseria gonorrhoeae GMMA vaccine.